Anti-inflammatory effects of macrolides—an underappreciated benefit in the treatment of community-acquired respiratory tract infections and chronic inflammatory pulmonary conditions?

Kudoh, S. (1998). Erythromycin treatment in diffuse panbronchiolitis. Current Opinion in Pulmonary Medicine4, 116–21.

Kudoh, S. & Kimura, H. (1984). Clinical effect of low-dose long-term administration of macrolides on diffuse panbronchiolitis. Nihon Kyobu Shikkan Gakkai Zasshi254, Suppl., 254.

Kudoh, S., Azuma, A., Yamamoto, M. et al. (1998). Improvement of survival in patients with diffuse panbronchiolitis treated with low-dose erythromycin. American Journal of Respiratory and Critical Care Medicine157, 1829–32.

Kudoh, S., Uetake, T., Hagiwara, K. et al. (1987). Clinical effects of low-dose long-term erythromycin chemotherapy on diffuse panbronchiolitis. Nihon Kyobu Shikkan Gakkai Zasshi25, 632–42.

Yamamoto, M., Kondo, A., Tamura, M. et al. (1990). Long-term therapeutic effects of erythromycin and new quinolone antibacterial agents on diffuse panbronchiolitis. Nihon Kyobu Shikkan Gakkai Zasshi28, 1305–13.

Schultz, M. J. (2004). Macrolide activities beyond their antimicrobial effects: macrolides in diffuse panbronchiolitis and cystic fibrosis. Journal of Antimicrobial Chemotherapy54, 21–8.

Goswami, S. K., Kivity, S. & Marom, Z. (1990). Erythromycin inhibits respiratory glycoconjugate secretion from human airways in vitro. American Review of Respiratory Diseases141, 72–8.

Tamaoki, J., Isono, K., Sakai, N. et al. (1992). Erythromycin inhibits Cl secretion across canine tracheal epithelial cells. European Respiratory Journal5, 234–8.

Tamaoki, J., Takeyama, K., Tagaya, E. et al. (1995). Effect of clarithromycin on sputum production and its rheological properties in chronic respiratory tract infections. Antimicrobial Agents and Chemotherapy39, 1688–90.

Tagaya, E., Tamaoki, J., Kondo, M. et al. (2002). Effect of a short course of clarithromycin therapy on sputum production in patients with chronic airway hypersecretion. Chest122, 213–8.

Rubin, J.-I, Druce, H., Ramirez, O. E. et al. (1997). Effect of clarithromycin on nasal mucus properties in healthy subjects and in patients with purulent rhinitis. American Journal of Respiratory and Critical Care Medicine155, 2018–23.

Kadota, J.-I., Sakito, O., Kohno, S. et al. (1993). A mechanism of erythromycin treatment in patients with diffuse panbronchiolitis. American Review of Respiratory Diseases147, 153–9.

Sakito, O., Kadota, J.-I., Kohno, S. et al. (1996). Interleukin 1β, tumor necrosis factor α and interleukin 8 in bronchoalveolar lavage fluid of patients with diffuse panbronchiolitis: a potential mechanism of macrolide therapy. Respiration63, 42–8.

Amayasu, H., Yoshida, S., Ebana, S. et al. (2000). Clarithromycin suppresses bronchial hyperresponsiveness associated with eosinophilic inflammation in patients with asthma. Annals of Allergy, Asthma, & Immunology84, 594–8.

Koh, Y. Y., Lee, M. H., Sun, Y. H. et al. (1997). Effect of roxithromycin on airway responsiveness in children with bronchiectasis: a double-blind, placebo-controlled study. European Respiratory Journal10, 994–9.

Tsang, K. W. T., Ho, P.-I., Chan, K.-n. et al. (1999). A pilot study of low-dose erythromycin in bronchiectasis. European Respiratory Journal13, 361–4.

Gerhardt, S. G., McDyer, J. F., Girgis, R. E. et al. (2003). Maintenance azithromycin therapy for bronchiolitis obliterans syndrome: results of a pilot study. American Journal of Respiratory and Critical Care Medicine168, 121–5.

Equi, A., Balfour-Lynn, I. M., Bush, A. et al. (2002). Long term azithromycin in children with cystic fibrosis: a randomised, placebo-controlled crossover trial. Lancet360, 978–84.

Wolter, J., Seeney, S., Bell, S. et al. (2002). Effect of long term treatment with azithromycin on disease parameters in cystic fibrosis: a randomised trial. Thorax57, 212–6.

Saiman, L., Marshall, B. C., Mayer-Hamblett, N. et al. (2003). Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. Journal of the American Medical Association290, 1749–56.

Howe, R. A. & Spencer, R. C. (1997). Macrolides for the treatment of Pseudomonas aeruginosa infections. Journal of Antimicrobial Chemotherapy40, 153–5.

Kobayashi, H. (1995). Biofilm disease: its clinical manifestation and therapeutic possibilities of macrolides. American Journal of Medicine99, Suppl. 6A, 26S–30S.

Kobayashi, H. (2001). Airway biofilm disease. International Journal of Antimicrobial Agents17, 351–6.

Yasuda, H., Ajiki, Y., Koga, T. et al. (1993). Interaction between biofilms formed by Pseudomonas aeruginosa and clarithromycin. Antimicrobial Agents and Chemotherapy37, 1749–55.

Vranes, J. (2000). Effect of subminimal inhibitory concentrations of azithromycin on adherence of Pseudomonas aeruginosa to polystyrene. Journal of Chemotherapy12, 280–5.

Ichimiya, T., Yamasaki, T. & Nasu, M. (1994). In-vitro effects of antimicrobial agents on Pseudomonas aeruginosa biofilm formation. Journal of Antimicrobial Chemotherapy34, 331–41.

Bui, K. Q., Banevicius, M. A., Nightingale, C. H. et al. (2000). In vitro and in vivo influence of adjunct clarithromycin on the treatment of mucoid Pseudomonas aeruginosa. Journal of Antimicrobial Chemotherapy45, 57–62.

Takeoka, K., Ichimiya, T., Yamasaki, T. et al. (1998). The in vitro effect of macrolides on the interaction of human polymorphonuclear leukocytes with Pseudomonas aeruginosa in biofilm. Chemotherapy44, 190–7.

Yanagihara, K., Tomono, K., Sawai, T. et al. (2000). Combination therapy for chronic Pseudomonas aeruginosa respiratory infection associated with biofilm formation. Journal of Antimicrobial Chemotherapy46, 69–72.

Tateda, K., Ishii, Y., Matsumoto, T. et al. (1996). Direct evidence for antipseudomonal activity of macrolides: exposure-dependent bactericidal activity and inhibition of protein synthesis by erythromycin, clarithromycin, and azithromycin. Antimicrobial Agents and Chemotherapy40, 2271–5.

Tateda, K., Comte, R., Pechere, J.-C. et al. (2001). Azithromycin inhibits quorum sensing in Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy45, 1930–3.

Molinari, G., Guzmán, C. A., Pesce, A. et al. (1993). Inhibition of Pseudomonas aeruginosa virulence factors by subinhibitory concentrations of azithromycin and other macrolide antibiotics. Journal of Antimicrobial Chemotherapy31, 681–8.

Nguyen, T., Louie, S. G., Beringer, P. M. et al. (2002). Potential role of macrolide antibiotics in the management of cystic fibrosis lung disease. Current Opinion in Pulmonary Medicine8, 521–8.

Yoshii, I., Nishimura, H., Yoshikawa, T. et al. (2001). Therapeutic possibilities of long-term roxithromycin treatment for chronic diffuse sclerosing osteomyelitis of the mandible. Journal of Antimicrobial Chemotherapy47, 631–7.

Heffelfinger, J. D., Dowell, S. F., Jorgensen, J. H. et al. (2000). Management of community-acquired pneumonia in the era of pneumococcal resistance: a report from the Drug-Resistant Streptococcus pneumoniae Therapeutic Working Group. Archives of Internal Medicine160, 1399–408.

Macfarlane, J., Boswell, T., Douglas, G. et al. (2001). BTS guidelines for the management of community acquired pneumonia in adults. Thorax56, Suppl. IV, iv1–64.

Memish, Z. A., Shibl, A. M., Ahmed, Q. A. A. et al. (2002). Guidelines for the management of community-acquired pneumonia in Saudi Arabia: a model for the Middle East region. International Journal of Antimicrobial Agents20, Suppl. 1, S1–12.

Pallares, R., Linares, J., Vadillo, M. et al. (1995). Resistance to penicillin and cephalosporins and mortality from severe pneumococcal pneumonia in Barcelona, Spain. New England Journal of Medicine333, 474–80.

Mandell, L. A., Bartlett, J. G., Dowell, S. F. et al. (2003). Update of practice guidelines for the management of community-acquired pneumonia in immunocompetent adults. Clinical Infectious Diseases37, 1405–33.

Jung, S., Song, J., Oh, W. et al. (2002). Clinical outcomes of pneumococcal pneumonia by antibiotic-resistant strains in Asian countries; the Asian Network for Surveillance of Resistant Pathogens (ANSORP) study. In Abstracts of the Forty-second Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA, 2002. Abstract L-991, p. 360. American Society for Microbiology, Washington, DC, USA.

Amsden, G. W., Baird, I. M., Simon, S. et al. (2003). Efficacy and safety of azithromycin versus levofloxacin in the outpatient treatment of acute bacterial exacerbations of chronic bronchitis. Chest123, 772–7.

Lode, H., File, T. M., Jr, Mandell, L. et al. (2002). Oral gemifloxacin versus sequential therapy with intravenous ceftriaxone/oral cefuroxime with or without a macrolide in the treatment of patients hospitalized with community-acquired pneumonia: a randomized, open-label, multicenter study of clinical efficacy and tolerability. Clinical Therapeutics24, 1915–36.

Stahl, J. E., Barza, M. D., Desfardin, J. et al. (1999). Effect of macrolides as part of initial empiric therapy on length of stay in patients hospitalized with community-acquired pneumonia. Archives of Internal Medicine159, 2576–80.

Mufson, M. A. & Stanek, R. J. (1999). Bacteremic pneumococcal pneumonia in one American city: a 20-year longitudinal study, 1978–1997. American Journal of Medicine107, 34S–43S.

Martinez, J. A., Horcajada, J. P., Almela, M. et al. (2003). Addition of a macrolide to a β-lactam-based empirical antibiotic regimen is associated with lower in-hospital mortality for patients with bacteremic pneumococcal pneumonia. Clinical Infectious Diseases36, 389–95.

Weiss, K., Cortes, L., Beaupre, A., et al. (2002). Clinical characteristics, initial presentation and impact of treatment on mortality in bacteremic Streptococcus pneumoniae pneumonia (BSPP). In Abstracts of the Forty-second Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA, 2002. Abstract L-987, p. 359. American Society for Microbiology, Washington, DC, USA.

Gupta, A. K., Rai, S., Farag, B. et al. (2002). Comparative analysis of levofloxacin (LV) vs ceftriaxone (CX)/azithromycin (AZ) in the treatment of community-acquired pneumonia (CAP): length of stay. In Abstracts of the Forty-second Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA, 2002. Abstract L-981, p. 357. American Society for Microbiology, Washington, DC, USA.

Gleason, P. P., Meehan, T. P., Fine, J. M. et al. (1999). Associations between initial antimicrobial therapy and medical outcomes for hospitalized elderly patients with pneumonia. Archives of Internal Medicine159, 2562–72.

Brown, R. B., Iannini, P., Gross, P. et al. (2003). Impact of initial antibiotic choice on clinical outcomes in community-acquired pneumonia: analysis of a hospital claims-made database. Chest123, 1503–11.

Lonks, J. R., Garau, J., Gomez, L. et al. (2002). Failure of macrolide antibiotic treatment in patients with bacteremia due to erythromycin-resistant Streptococcus pneumoniae. Clinical Infectious Diseases35, 556–64.

Trowbridge, J. F., Artymowicz, R. J., Lee, C. E. et al. (2002). Antimicrobial selection and length of hospital stay in patients with community-acquired pneumonia. Journal of Clinical Outcomes Management9, 613–9.

Lentino, J. R. & Krasnicka, B. (2002). Association between initial empirical therapy and decreased length of stay among veteran patients hospitalized with community acquired pneumonia. International Journal of Antimicrobial Agents19, 61–6.

Meehan, T. P., Fine, M. J., Krumholz, H. M. et al. (1997). Quality of care, process, and outcomes in elderly patients with pneumonia. Journal of the American Medical Association278, 2080–4.

Battleman, D. S., Callahan, M. & Thaler, H. T. (2002). Rapid antibiotic delivery and appropriate antibiotic selection reduce length of hospital stay of patients with community-acquired pneumonia: link between quality of care and resource utilization. Archives of Internal Medicine162, 682–8.

Lehtomaki, K. (1988). Clinical diagnosis of pneumococcal, adenoviral, mycoplasmal and viral pneumonia in young men. European Respiratory Journal1, 324–9.

Jay, S. J., Johnson, W. G., Jr & Pierce, W. K. (1991). The radiographic resolution of Streptococcus pneumoniae pneumonia. New England Journal of Medicine293, 798–801.

Čulić, O., Eraković, V., Čepelak, I. et al. (2002). Azithromycin modulates neutrophil function and circulating inflammatory mediators in healthy human subjects. European Journal of Pharmacology450, 277–89.

Kolling, U. K., Hansen, F., Braun, J. et al. (2001). Leucocyte response and anti-inflammatory cytokines in community acquired pneumonia. Thorax56, 121–5.

Koch, C. C., Esteban, D. J., Chin, A. C. et al. (2000). Apoptosis, oxidative metabolism and interleukin-8 production in human neutrophils exposed to azithromycin: effects of Streptococcus pneumoniae. Journal of Antimicrobial Chemotherapy46, 19–26.

Inamura, K., Ohta, N., Fukase, S. et al. (2000). The effects of erythromycin on human peripheral neutrophil apoptosis. Rhinology38, 124–9.

Ives, T. J., Schwab, U. E., Ward, E. S. et al. (2001). Disposition and functions of clarithromycin in human THP-1 monocytes during stimulated and unstimulated conditions. Research Communications in Molecular Pathology & Pharmacology110, 183–208.

Chow, L. W. C., Yuen, K-Y., Woo, P. C. Y. et al. (2000). Clarithromycin attenuates mastectomy-induced acute inflammatory response. Clinical and Diagnostic Laboratory Immunology7, 925–31.